• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us
Sleep Diagnosis and Therapy

Sleep Diagnosis and Therapy

Official Publication of the American Sleep and Breathing Academy

FDA Scrutinizes Effects of Sleep Drugs

August 15, 2013 by admin

The NY Times jumped into the sleep-related media fray with a feature that addressed the flip side of sleep—waking up. Reporter Katie Thomas reports that the FDA is taking heightened interest in the issue thanks to new evidence that suggests the effects of well-known sleep drugs could persist into the day.

Of particular interest is a possible link between sleep drugs and car accidents. With studies showing about 60 million prescriptions for sleep aids in the United States last year, the problem (if it exists) could be widespread.

The NY Times points out that relative newcomers such as Intermezzo from Purdue Pharma could help pave the way for appropriate dosing guidelines. In 2011, the FDA recognized gender variability when it approved the sleep drug Intermezzo, which treats patients who wake up in the middle of the night.

Women get a lower dose of Intermezzo (active ingredient Zolpidem) and all users are warned to only take the drug if they have four hours or more of bedtime left. “The agency’s experience with Intermezzo,” writes Thomas, “along with other research, led it to order in January that the dosage for all drugs containing zolpidem — the active ingredient in Intermezzo, as well as Ambien and related generic sleep drugs — be halved for women.”

Despite the increased scrutiny for sleep drugs, the NY Times highlighted the inherent paradox of the sleep drug/sleepiness situation. “What we have to weigh here is that people who don’t sleep well are a hazard on the road because they do fall asleep while driving,” said Robert Voas, a senior research scientist at the Pacific Institute for Research and Evaluation and an expert on driving safety in the Times article. “There’s risks on both sides.”

Source: NY Times

Filed Under: Articles, Blog

Primary Sidebar

More to See

Snoring, American Sleep and Breathing Academy and the NY Times

August 23, 2022 By admin

Jazz Pharma Presents 17 New Posters for SLEEP 2022

June 6, 2022 By admin

Tags

apnea CPAP Health Home Sleep Home Sleep Testing insomnia narcolepsy obstructive sleep apnea Sleep sleep apnea sleep apnea symptoms sleep apnea syndrome sleep apnea treatment sleep appliances sleep buisness Sleep Business sleep center Sleep Centers sleep community sleep diagnosis sleep diagnostic sleep diagnostics sleep disease sleep disorder sleep disorder center sleep disordered breathing sleep disorders sleep heart health sleep industry sleeping Sleep Lab sleep labs sleep management sleep medicine sleep monitor sleep physicians sleep problems sleep studies sleep study sleep technologist sleep test sleep testing Technology therapy Treatment

Footer

About SleepDT

SleepDT Sleep Diagnosis and Therapy is a clinical Journal for allied Sleep Professionals, Neurologists, Psychiatrists, Pulmonologists, Primary Care Physicians, and other medical specialists. We also advocate on behalf of patient care in the field of Sleep Medicine

Recent

  • SUPPORT AND PROMOTE DENTAL SLEEP MEDICINE IN 2023!
  • Snoring, American Sleep and Breathing Academy and the NY Times
  • Jazz Pharma Presents 17 New Posters for SLEEP 2022
  • AJMC Hypes SLEEP 2022
  • Avadel Pharmaceuticals’ Stock Falls

NAVIGATION

  • Home
  • About Us
  • Blog
  • Subscribe to the Journal
  • Contact Us

Copyright © 2023 · Sleep Diagnosis and Therapy